Literature DB >> 17627531

Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Michael W Ferenczy1.   

Abstract

Herpes Simplex Virus Type 1 (HSV-1) infection is widespread and causes significant disease. A number of prophylactic vaccine strategies have elicited protective immunity in animal models, but no human vaccine has yet been effective. Asymptomatic HSV-1 infection is common, demonstrating that the immune system is able to control infection, despite failure to clear the virus. Therefore, therapeutic vaccination may be a viable strategy against HSV-1. This review will discuss the epidemiology, molecular biology, and immune response to HSV-1, prophylactic and therapeutic vaccine strategies, and the potential of future therapeutic HSV-1 vaccines to reduce or eliminate HSV-1 pathology.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17627531      PMCID： PMC3839066          DOI： 10.2174/138161207781039779

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


  202 in total

1.  Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines.

Authors:  S K Eo; S Lee; S Chun; B T Rouse
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 2.  The immune response to ocular herpes simplex virus type 1 infection.

Authors:  D J Carr; P Härle; B M Gebhardt
Journal:  Exp Biol Med (Maywood)       Date:  2001-05

3.  Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection.

Authors:  A Verschoor; M A Brockman; D M Knipe; M C Carroll
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

4.  Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus.

Authors:  M Franchini; C Abril; C Schwerdel; C Ruedl; M Ackermann; M Suter
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 5.  Sorting and transport of alpha herpesviruses in axons.

Authors:  M J Tomishima; G A Smith; L W Enquist
Journal:  Traffic       Date:  2001-07       Impact factor: 6.215

Review 6.  The role of HSV in the transmission and progression of HIV.

Authors:  T Schacker
Journal:  Herpes       Date:  2001-07

7.  Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0.

Authors:  Jesper Melchjorsen; Finn S Pedersen; Søren C Mogensen; Søren R Paludan
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes.

Authors:  L A Koutsky; R L Ashley; K K Holmes; C E Stevens; C W Critchlow; N Kiviat; C M Lipinski; P Wølner-Hanssen; L Corey
Journal:  Sex Transm Dis       Date:  1990 Apr-Jun       Impact factor: 2.830

9.  Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections.

Authors:  M K Breinig; L A Kingsley; J A Armstrong; D J Freeman; M Ho
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

10.  Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize immediate-early protein ICP27.

Authors:  T A Banks; E M Allen; S Dasgupta; R Sandri-Goldin; B T Rouse
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103
View more
  2 in total

1.  A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats.

Authors:  Mariarosaria Marinaro; Giovanni Rezza; Giuseppe Del Giudice; Valeriana Colao; Elvira Tarsitano; Michele Camero; Michele Losurdo; Canio Buonavoglia; Maria Tempesta
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

Review 2.  Herpes simplex virus interference with immunity: Focus on dendritic cells.

Authors:  Farías Ma; Duarte Lf; Tognarelli Ei; González Pa
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.